A research peptide blend is a single vial containing more than one peptide, lyophilised together at fixed ratios. Blends are common in the catalogue and uncommon in the literature, which creates a specific problem: the individual compounds are well studied, the combinations are generally not. This review covers what is actually in the three blends in this catalogue, why those particular groupings exist, and the analytical questions a multi-peptide vial raises that a single-peptide vial does not.
What a Blend Is, and What It Is Not
A blend is a co-lyophilised mixture. The peptides are dissolved together, frozen, and dried to a single cake, so reconstituting the vial yields all of them in one solution at the ratio the manufacturer set. It is not a new molecule, and it is not a complex: the constituents do not bond to one another. They are simply present together.
That distinction matters for how a blend should be read. Any property of a blend is the sum of its parts plus whatever happens when those parts share a solvent. There is no separate body of pharmacology for "Wolverine" or "Glow"; there is pharmacology for BPC-157, for TB-500, for GHK-Cu, and the combination inherits it.
What Is In Each Blend
The three blends in this catalogue are built from four peptides, in increasing complexity:
- Wolverine Blend — BPC-157 and TB-500. The two most studied tissue-repair peptides in the preclinical literature, and the simplest pairing.
- Glow Blend — BPC-157 (10mg), TB-500 (10mg) and GHK-Cu (50mg). Adds the copper tripeptide, which is the one constituent with substantial human dermal data.
- Klow Blend — GHK-Cu (50mg), TB-500 (10mg), BPC-157 (10mg) and KPV (10mg). Adds KPV, the C-terminal tripeptide of α-MSH.
Note the ratios rather than just the names. GHK-Cu is present at five times the mass of the other constituents in both blends that contain it, because the dermal literature on GHK-Cu works at substantially higher quantities than the tissue-repair literature on BPC-157.
Why These Particular Groupings
The rationale offered for each combination is mechanistic complementarity rather than demonstrated synergy, and it is worth being precise about that difference.
BPC-157 and TB-500 are grouped because they are studied in overlapping models by different proposed routes: BPC-157 in the angiogenic and growth-factor literature, TB-500 as a synthetic fragment of thymosin β4 acting on actin sequestration and cell migration. GHK-Cu is added where extracellular-matrix and dermal endpoints are the interest, since it is the constituent with real human dermal evidence. KPV is added as the anti-inflammatory arm, being the α-MSH fragment that retains the parent peptide's inflammatory signalling without its melanocortin pigmentation activity.
What does not exist, for any of these three combinations, is a controlled study of the combination itself. Each constituent has its own literature. The blend does not. Any expectation of additive or synergistic behaviour is inference from the separate mechanisms, not an observed result, and it should be labelled that way.
The Analytical Question a Blend Raises
A single-peptide vial has a straightforward certificate of analysis: one identity by mass spectrometry, one purity figure by HPLC. A multi-peptide vial does not, and this is the most important practical difference between a blend and a solo compound.
- Purity of what? A single percentage on a four-peptide vial is ambiguous unless the document states what it refers to. Purity is a property of a peak, not of a mixture.
- Ratio verification. The stated masses are a claim about proportions. Confirming them requires quantification against reference standards, which is a different and more demanding analysis than a purity run.
- Co-elution. Peptides of similar hydrophobicity can elute at overlapping retention times on a standard reversed-phase gradient, which can mask a constituent or inflate an apparent purity figure.
A certificate for a blend is therefore more informative when it reports each constituent separately. How to read a certificate of analysis covers which fields carry that information and which do not.
Reconstitution and Handling
A co-lyophilised cake is reconstituted as one unit, so the constituents cannot be separated after the fact and the ratio is fixed at manufacture. Stability is governed by the least stable constituent rather than by an average, which is the conservative assumption to work from. General handling is covered in research peptide storage, shipping and handling; nothing about a blend changes the underlying requirement that lyophilised peptides are hygroscopic and are held cold.
How to Evaluate a Blend
Three questions separate a well-documented blend from a poorly documented one, and none of them is about the name on the vial:
- Does the certificate identify every constituent, or only report one number?
- Are the stated masses supported by quantification, or only asserted on the label?
- Is the evidence cited for the combination actually about the combination, or about each ingredient separately?
The third is the one most often answered loosely. For these three blends the honest answer is that the evidence is constituent-level, and a supplier that says otherwise is overstating what has been published.
References & primary sources
The literature below is for the individual constituents. No controlled study of these specific combinations is cited, because none has been published; that absence is the point of the section above.
- Sikiric P, Seiwerth S, Rucman R, et al. (2018) Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design 24:1990-2001.
- Goldstein AL, Hannappel E, Sosne G, Kleinman HK. (2012) Thymosin beta4: a multi-functional regenerative peptide. Expert Opinion on Biological Therapy 12:37-51.
- Pickart L, Margolina A. (2018) Regenerative and protective actions of the GHK-Cu peptide. International Journal of Molecular Sciences 19:1987.
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, et al. (2008) PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology 134:166-178.
- United States Pharmacopeia. General Chapter <1086> Impurities in Drug Substances and Drug Products. usp.org.
Questions and answers
What is a research peptide blend?
A single vial containing two or more peptides co-lyophilised together at fixed ratios. The peptides are mixed, not bonded, so reconstituting the vial yields all of them in one solution at the proportions set during manufacture.
What is in the Wolverine, Glow and Klow blends?
Wolverine is BPC-157 and TB-500. Glow is BPC-157 (10mg), TB-500 (10mg) and GHK-Cu (50mg). Klow is GHK-Cu (50mg), TB-500 (10mg), BPC-157 (10mg) and KPV (10mg). GHK-Cu is present at roughly five times the mass of the other constituents in both blends containing it.
Is there published research on peptide blends specifically?
Not for these combinations. Each individual constituent has its own published literature, but controlled studies of the blends themselves have not been published. Any expectation of additive or synergistic behaviour is inference from separate mechanisms rather than an observed result.
How should a certificate of analysis for a blend differ from a single peptide?
It should report each constituent separately. A single purity percentage on a multi-peptide vial is ambiguous, because purity describes a chromatographic peak rather than a mixture. Verifying the stated ratios additionally requires quantification against reference standards, which is a different analysis from a purity run.
Can the peptides in a blend be separated after reconstitution?
No. The constituents are co-lyophilised into one cake, so the ratio is fixed at manufacture and the vial is reconstituted as a single unit.